---
schema_version: "secwatch.filing_event.v1"
accession: "0001846253-23-000093"
form_type: "8-K"
ticker: "OABI"
cik: "0001846253"
company_name: "OmniAb, Inc."
filed_at: "2023-08-10T23:59:59+00:00"
generated_at: "2026-06-11T19:13:40.443437+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# OmniAb Q2 2023 revenue $6.9M, net loss $14.7M; adds four partners including Merck

## Summary
- Q2 revenue $6.9M (vs $7.2M YoY); net loss $14.7M ($0.15/share) vs $10.3M loss YoY.
- H1 revenue $23.9M (vs $16.8M) driven by $10M milestone from TECVAYLI first commercial sale in EU.
- Added 4 new partners: Merck, Neurocrine, Stanford, Seattle Children's; total active programs 305.
- Batoclimab BLA accepted in China for gMG; IMVT-1402 Phase 1 initiated; GSK milestone $2.0M earned.
- Cash and equivalents $103.1M; expects year-end cash slightly higher than 2022.

## SEC filing metadata
- accession: 0001846253-23-000093
- form_type: 8-K
- ticker: OABI
- cik: 0001846253
- company_name: OmniAb, Inc.
- filed_at: 2023-08-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1846253/000184625323000093/0001846253-23-000093-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1846253/000184625323000093/lgnd-20230810.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001846253-23-000093
- JSON: https://secwatch.observer/filing/0001846253-23-000093.json
- Plain text: https://secwatch.observer/filing/0001846253-23-000093.txt

## Key facts
- Earnings Releases
  OmniAb, Inc. reported the three and six months ended June 30, 2023 results: revenue $6.9 million, net income $14.7 million, or $0.15 per share, EPS $0.15 per share.
  - Period: the three and six months ended June 30, 2023
  - Revenue: $6.9 million
  - Net income: $14.7 million, or $0.15 per share
  - EPS: $0.15 per share
  - Result: reported results
  source text: related to our current partners as well as to securing additional partnerships,” he added. Second Quarter 2023 Financial Results Revenue for the second quarter of 2023 was $6.9 million, compared with $7.2 million for the same period in 2022. Milestone revenue was higher due to progress with the batoclimab program. Service revenue was lower primarily related to
  evidence_url: https://www.sec.gov/Archives/edgar/data/1846253/000184625323000093/0001846253-23-000093-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.